anastrozole + palbociclib

Anastrozole + palbociclib is an oral combination regimen used primarily for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Anastrozole is a non-steroidal aromatase inhibitor that reduces estrogen production by inhibiting the aromatase enzyme, thereby decreasing tumor growth in estrogen-dependent cancers. Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression from G1 to S phase by preventing phosphorylation of retinoblastoma protein, leading to reduced proliferation of cancer cells. The combination has demonstrated efficacy and safety in clinical trials as first-line therapy for postmenopausal women with HR+/HER2- advanced breast cancer, and it may also be used in other settings such as neoadjuvant therapy or in combination with additional agents for specific subtypes[1][3][5][6].